Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Revenue
Apontis Pharma AG
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Revenue
€37m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Revenue
$314k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Revenue
€46.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
Merck KGaA
XETRA:MRK
|
Revenue
€21B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Revenue
€1.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Revenue
€101.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Revenue?
Revenue
37m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Revenue amounts to 37m EUR.
What is Apontis Pharma AG's Revenue growth rate?
Revenue CAGR 3Y
-2%
Over the last year, the Revenue growth was -34%. The average annual Revenue growth rates for Apontis Pharma AG have been -2% over the past three years .
You don't have any saved screeners yet